Treatment with anti-SARS-CoV-2 monoclonal antibodies in pregnant and postpartum women: first experiences in Florence, Italy

• DOI: 10.1007/s15010-022-01777-z
• Publication Date: 2022-03-07T17:02:52Z
• Authors: Tommaso Manciulli; Giulia Modi; Irene Campolmi; Beatrice Borchi; Michele Trotta; Michele Spinicci; Filippo Lagi; Alessandro Bartoloni; Lorenzo Zammarchi
• Keywords: Adult; Original Paper; Postpartum Period; Antibodies, Monoclonal; Infant; Antibodies, Monoclonal, Humanized; Antibodies, Viral; COVID-19; Casirivimab/imdevimab; Monoclonal antibodies; Pregnancy; SARS-CoV-2; mAbs; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Viral; Antiviral Agents; Female; Humans; Infant; Oxygen; Postpartum Period; Pregnancy; COVID-19; Antiviral Agents; COVID-19 Drug Treatment; 3. Good health; Oxygen; 03 medical and health sciences; 0302 clinical medicine; Pregnancy; Humans; Female

Pregnant and postpartum women are at increased risk of developing severe COVID-19. Monoclonal antibodies (mAbs) now widely used in high-income countries to treat mild moderate COVID-19 outpatients for disease. Very few data available on the use mAbs special populations, including pregnant women. Here we present our early experience with these two populations.Electronic records treated Careggi University Hospital, Florence, were retrieved. Relevant extracted (age, presence factors COVID-19, oxygen support, mAb type, gestational age, pregnancy status). When available, outcomes 28 days after administration also included.From March 1st September 30th 2021, eight have been center. The median age was 31 years (IQR 30-33.5, range 29-38), 24 weeks. Seven patients had additional factors. According Italian disposition, all received casirivimab/imdevimab, five receiving a 2.4 mg dose 8 g dose. Eight improved. One developed myocarditis, considered complication. Another required transient increase low flow support before improving being discharged. At follow-up, clinically recovered. We did not observe related adverse events.Although preliminary should be interpreted caution, it is remarkable how well tolerated by Further this population collected but considered. Even thus oral antivirals becoming they recommended This may specifically benefit from treatment last generation mAbs.